TRIPS-Plus Provisions and Access to Technologies:

Similar documents
Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board

TRIPS, FTAs and BITs: Impact on Domestic IP- and Innovation Strategies in Developing Countries

Submission to the Productivity Commission inquiry into Intellectual Property Arrangements

Economics of IPRs and patents

IPRs and Public Health: Lessons Learned Current Challenges The Way Forward

Flexibilities in the Patent System

Flexibilities in the Patent System

Development. Prepared for Intellectual Property Task Force meeting 2009 University of Manchester, June 22-23, 2009

Measuring Intangible Assets (IP & Data) for the Knowledge-based and Data-driven Economy

TRIPS and Access to Medicines. WR Briefing

Innovation, Creativity, and Intellectual Property Rights

ACCOUNTING TREATMENT OF INTELLECTUAL PROPERTY IN THE PHARMACEUTICAL INDUSTRY

INTELLECTUAL PROPERTY AND ECONOMIC GROWTH

Settlement of Pharma Disputes and Competition Law in Korea

Topic 2: The Critical Role of IP Policies in Modern Economies

Carnegie Endowment for International Peace

strong patents, weak patents and evergreening: should patents for drugs be challenged more often? Giancarlo Del Corno Studio Legale Sena e Tarchini

WIPO Sub-Regional Workshop on Patent Policy and its Legislative Implementation

Regional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities

OECD s Innovation Strategy: Key Findings and Policy Messages

If you can t do it better, why do it? -- Herbert H. Dow

UNCTAD Ad Hoc Expert Meeting on the Green Economy: Trade and Sustainable Development Implications November

Topic 2: Patent-related Flexibilities in Multilateral Treaties and Their Importance for Developing Countries and LDCs

Research Patents in Biotech SMEs

Globalizing IPR Protection: How Important Might RTAs Be?

University IP and Technology Management. University IP and Technology Management

AAAS Project on Science and Intellectual Property in the Public Interest

Chapter 25 Intellectual Property Rights and Economic Policy (2000-present)

WHO workshop on IP and Vaccines. Geneva 19 th -20 th April Introduction to the IP issues Christopher Garrison Consultant to WHO

Patents and Intellectual Property

B) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:

REPUBLIC ACT 10055: Philippine Technology Transfer Act of 2009

TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY ACCESS TO MEDICINE: Exploitation of pharmaceutical patents: compulsory licences SESSION 4

Role of Intellectual Property in Science, Technology and Development

Changing role of the State in Innovative Activity The Indian Experience. Sunil Mani

Standing Committee on the Law of Patents

Access to Medicines, Patent Information and Freedom to Operate

VTIP in 20 Minutes What You Need to Know

BASED ECONOMIES. Nicholas S. Vonortas

WIPO REGIONAL SEMINAR ON SUPPORT SERVICES FOR INVENTORS, VALUATION AND COMMERCIALIZATION OF INVENTIONS AND RESEARCH RESULTS

PROTECTING INVENTIONS: THE ROLE OF PATENTS, UTILITY MODELS AND DESIGNS

Evaluating a Report of Invention & Licensing. Technology Development Boot Camp Peter Liao March 25, 2013

Unionization, Innovation, and Licensing. Abstract

ROLE OF INTELLECTUAL PROPERTY RIGHTS IN DEVELOPING COUNTRIES -ASHWINI SANDU.

IP and Technology Management for Universities

Patenting Strategies. The First Steps. Patenting Strategies / Bernhard Nussbaumer, 12/17/2009 1

UNCITRAL Third International Colloquium on Secured Transactions Session on Contractual Guide on IP Licensing (Vienna, March 3, 2010)

Patent Working Requirements Historical and Comparative Perspectives

SEMINAR: INTELLECTUAL PROPERTY ARRANGEMENTS: IMPLICATIONS FOR DEVELOPING COUNTRY PRODUCTIVE CAPABILITIES IN THE SUPPLY OF ESSENTIAL MEDICINES.

Nitya Nanda. The Energy and Resources Institute (TERI)

Practical measures to encourage the diffusion of green technologies: Licensing Fast tracking of green patents The GreenXchange Platform

Intellectual property governance and strategic value creation:

Protecting Intellectual Property under TRIPS, FTAs and BITs: Conflicting Regimes or Mutual Coherence?

Sectoral Patterns of Technical Change

PROTECTION OF INTELLECTUAL PROPERTY

Practical Strategies for Biotechnology and Medical Device Companies to Manage Intellectual Property Rights

Innovation Office. Intellectual Property at the Nelson Mandela University: A Brief Introduction. Creating value for tomorrow

Intellectual Property

Maximizing Innovation Funding for Technology Development. MNP SR&ED Team. Presented by: Date:

PATENT PROTECTION FOR PHARMACEUTICAL PRODUCTS IN CANADA CHRONOLOGY OF SIGNIFICANT EVENTS

A HOLISTIC APPROACH TO TECHNOLOGY LICENSING IN THAILAND

TRIPS and Access to Medicines. The Story so far

Formation and Management

Chapter 8. Technology and Growth

Issues and Possible Reforms in the U.S. Patent System

Strategic use of patents: The case of patent trolls

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities

Review essay. Intellectual property regulation and international trade: national and global economic perspectives. Alexander Cuntz

TECHNOLOGY TRANSFER: Challenges, Opportunities and Successful Cases. Phan Quoc Nguyen

UNCTAD-ICTSD Project on IPRs and Sustainable Development

WIPO Development Agenda

IP KEY SOUTH EAST ASIA ANNUAL WORK PLAN FOR 2018

WIPO-WASME Program on Practical Intellectual Property Rights Issues for Entrepreneurs, Economists, Bankers, Lawyers and Accountants

Potential developments of patents in Med Regions, Egypt, Morocco, Tunisia. Ahmed Bounfour Vincent Delbecque Tamer Taha Walid Hadhri Héla Masmoudi

U.S. Patent-Antitrust Interface. Alden F. Abbott, Heritage Foundation Oxford Competition Law Centre June 28, 2014

POLICY PHILOSOPHY DEFINITIONS AC.2.11 INTELLECTUAL PROPERTY. Programs and Curriculum. APPROVED: Chair, on Behalf of SAIT s Board of Governors

Building a Competitive Edge: Protecting Inventions by Patents and Utility Models

Slide 15 The "social contract" implicit in the patent system

The Green Economy: Trade and Sustainable Development Implications. From Rio to Rio:Technology Transfer, Innovation and Intellectual Property

Patenting, Innovation & Technology Transfer : The CSIR Experience

Standing Committee on the Law of Patents

BOOK REVIEW INTELLECTUAL PROPERTY, PHARMACEUTICALS AND PUBLIC HEALTH: ACCESS TO DRUGS IN DEVELOPING COUNTRIES

Technology Transfer and Intellectual Property Best Practices

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.

Issues at the Intersection of IP and Competition Policy

NON-PAPER ON THE PROJECT ON INTELLECTUAL PROPERTY AND TECHNOLOGY TRANSFER COMMON CHALLENGES BUILDING SOLUTIONS (DOCUMENT CDIP/4/7)

Rosatom Approach to IPR Management in Collaborative Projects on Innovations

Statement by Executive Director, South Centre, Martin Khor, to the Open Working Group on Sustainable Development Goals, 9 Dec 2013

Patients Must Have Immediate Access to Affordable Generic Medicines at Day One After Patent Expiry

Introduction to IP: Some Basics of Patents, Trademarks, & Trade Secrets

Intellectual Property Rights and Development CARLOS M. CORREA

UHS Intellectual Property Policies and Procedures

COMPETITIVNESS, INNOVATION AND GROWTH: THE CASE OF MACEDONIA

NEW TREATY DEVELOPMENT AND HARMONIZATION OF INTELLECTUAL PROPERTY LAW

INTELLECTUAL PROPERY RIGHTS: ECONOMY Vs SCIENCE &TECHNOLOGY. Sankar Narayanan.S System Analyst, Anna University Coimbatore

The TRIPS Tightrope public health, innovation, incentives and access

CRS Report for Congress

THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT

IP For Entrepreneurs. For Background Education Only NOT LEGAL ADVICE

The United Arab Emirates is ranked 38th in the GII 2018, dropping 3 positions from last year.

Transcription:

TRIPS-Plus Provisions and Access to Technologies: Implications for the Trans-Pacific Partnership Walter G. Park, American University 11 May 2012

Outline Notion of Optimal IPRs IPRs and Technology Transfer Previous Research TRIPS-Plus Free Trade Agreements (FTA) Impact on Technology Transfer Implications for FTAs

I. Optimal IPRs Costs and Benefits IPRs solve a missing market problem Public Goods (Knowledge is non-rival and non-excludable) Tradeoff Limited Competition, Monopoly Pricing, and Higher Cost of R&D for follow-on inventors

I. Optimal IPRs Social Welfare Conventional View Strength of IPRs

I. Optimal IPRs Grossman & Lai (2004), Kim, Lee, Park, and Choo (2012) Social Welfare Developed Developing Strength of IPRs

II. IPRs and Technology Transfer Will stronger IPRs enhance access to new products & processes via Exports, FDI, and Licensing by Developed Countries? [Key Premise of TRIPS] Ambiguous: Market Expansion effect and Market Power effect of IPRs Again, non-linear relationship between IPRs and Tech Transfer

II. IPRs and Technology Transfer Net effect (i.e., market expansion vs. market power effect) depends on size of market and imitative capacities of host Volume and Composition effects Ownership, Location, and Internalization (OLI) IPR increases associated with sequencing: exports FDI arms-length licensing Matters for knowledge diffusion, employment, capacity to satisfy demand

II. IPRs and Technology Transfer Empirical Evidence* Level and mode of tech transfer respond to IPRs. Effects vary by industry, type of intangible asset, and level of economic development of host country Conditional on other factors (human capital, wages, market size, taxes, governance, ) Presence of Alternative Means of Appropriation Caveats IPR has a nonlinear (inverted-u) effect. Thus, it is conducive to tech transfer in South if we raise levels from zero We don t observe internal market competition, pricing strategies, and distribution of sales (access for the poor). * See Park and Lippoldt (2012), forthcoming in Hall et al. (eds.) for a survey

III. TRIPS-Plus FTAs Raise strength of IPRs in developing country partner(s) Controversy: whether they push IP strength beyond the optimal level. Market power would then dominate any market expansion effects of IPR on inward technology diffusion. Selected previous studies International Intellectual Property Institute (2011) Oxfam International (2007) Collins-Chase (2008) U Penn Law Review, Lindstrom (2010) NYU Law Review

III. TRIPS-Plus FTAs Sample IPR Provisions Broader Scope (e.g., new uses found for a drug) Data Exclusivity (e.g., extend period of protection for test data) Patent linkage (e.g., register generics only after a patent expires) Limits on compulsory licensing (e.g., for national emergencies or anticompetitive abuses) Limits on parallel imports (e.g. arbitrage: access to cheaper sources) Requirement to join conventions not required by TRIPS (e.g. PCT, WCT, WPPT, Brussels Convention)

III. TRIPS-Plus FTAs These provisions offset flexibility in TRIPS Likely to raise the strength of local IPRs above the level appropriate for their stage of economic development. If so, adoption of TRIPS-Plus would enhance market power of patent holders and producers Reduced Supply and Increased Prices A Question is Why? What might be the underlying drivers behind developed countries push for TRIPS-Plus FTAs?

Economics 101 Normal Market Price Supply Demand Quantity

Economics 101 Medicines Price Supply Demand Quantity

Economics 101 Medicines Price Supply Demand Quantity

Economics 101 Medicines Price DEMAND is INELASTIC Bias towards higher Prices, Because as P increases, Q decreases, but % change in P greater than % drop in Q. Thus, revenue rises Demand Quantity

Economics 101 Medicines Price Reduced Supply Supply Demand Quantity

Public Choice 101 Special Interests, Regulatory Capture, and Revolving Door IP is a highly, complex subject. Policymakers, Courts Attorneys and Agents Clients (IP Owners), Associations

Public Choice 101 Thus, TRIPS-Plus provisions maximize private welfare, not social welfare. Markets require property rights, rule of law, price flexibility. Public sector failures can distort markets.

IV. Implications for FTAs Important to preserve TRIPS flexibilities Compulsory licensing for insufficient working within a reasonable period of time. Research Exemptions. TRIPS-Plus provisions not vital to dynamic incentives for Northern private sector innovation. Drug costs recouped from developed country markets Patent protection isn t the only (or even main) determinant of innovation. Role of public sector R&D in essential goods.